BOSTON– Elucid, an AI-driven medical technology company focused on improving precision in the diagnosis and treatment of atherosclerosis, has announced the appointment of Dr. Richard E. Kuntz and Dr. Shamiram Feinglass to its Board of Directors. The announcement was made during the Society of Cardiovascular Computed Tomography (SCCT) Annual Meeting in Montreal.
The addition of these two seasoned healthcare leaders comes as Elucid accelerates the clinical research and commercialization strategy for its PlaqueIQ™ technology—an FDA-cleared, non-invasive coronary plaque analysis platform—and advances development of its investigational fractional flow reserve (FFR) prediction model. PlaqueIQ is the first and only plaque assessment software cleared by the FDA that is based on objective histology rather than subjective visual estimates from coronary CT angiography (CCTA). It quantifies and classifies plaque based on ground-truth histology, the gold standard for assessing plaque composition, with the goal of helping physicians deliver personalized treatment decisions based on actual disease characteristics instead of population-based risk models.
Dr. Kuntz is the former Senior Vice President and Chief Medical and Scientific Officer of Medtronic plc and brings extensive experience in clinical trial strategy and interventional cardiology. Before joining Medtronic, he founded the Harvard Clinical Research Institute (HCRI), where he led numerous NIH and FDA-coordinated multicenter clinical trials. He previously served as an associate professor of medicine at Harvard Medical School and as an interventional cardiologist at Brigham and Women’s Hospital, where he also headed the Division of Clinical Biometrics. He has authored more than 250 original scientific publications.
Dr. Feinglass is a Managing Director at Manatt Health and a globally recognized expert in healthcare policy, market access, and regulatory strategy. She has held senior executive roles at major life sciences companies including Danaher and Zimmer-Biomet, and worked closely with policymakers around the world to influence healthcare legislation and access. Her regulatory experience includes service at the U.S. Centers for Medicare and Medicaid Services (CMS), and she is a retired commander in the U.S. Public Health Service. Dr. Feinglass is also on the faculty at the Johns Hopkins Bloomberg School of Public Health and serves on the Board of Directors of Sandoz AG.
“We are honored that Dr. Richard E. Kuntz and Dr. Shamiram Feinglass have joined Elucid’s Board of Directors,” said Kelly Huang, PhD, CEO of Elucid. “Rick lends an important and experienced interventional cardiology view, as well as expertise in clinical trial strategy and execution, and product innovation strategy. Coupled with Shami’s unparalleled expertise in market access, policy making, and regulatory strategy, the two will be invaluable as we push forward our vision of a future where cardiac care is personalized, precision patient care versus risk factor and population-based care.”
